SNCA Share Price | Palisade Bio, Inc. Stock Analysis & Recommendation

Q: What does Palisade Bio, Inc. do?

Overview: Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases of unmet medical need within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) Market cap: USD 3.09 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.35 Return on Equity: -246.48% Price to Book: 0.58Contact Details: Address: 20271 Goldenrod Ln Ste 2024, GERMANTOWN MD: 20876 Tel: 1 301 3664841 Fax: 1 302 7301370 Website: https://senecabio.com/

Q: Is Palisade Bio, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Palisade Bio, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, as indicated by the daily moving averages and the bearish signals from Dow Theory and Bollinger Bands. The weekly MACD shows a mildly bullish trend, but this is overshadowed by the overall bearish indicators. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -63.76% versus the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.74 M

Shareholding (Sep 2025)

FII

0.02%

Held by 3 FIIs

DII

99.95%

Held by 0 DIIs

Promoter

0.00%

How big is Palisade Bio, Inc.?

22-Jun-2025

As of Jun 18, Palisade Bio, Inc. has a market capitalization of 3.09 million and reported net sales of 0.00 million with a net profit of -13.14 million over the last four quarters. Shareholder's funds are at 7.49 million and total assets at 10.88 million.

View full answer

What does Palisade Bio, Inc. do?

22-Jun-2025

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs. It has a market cap of $3.09 million and reported a net profit loss of $2 million as of March 2025.

View full answer

Who are in the management team of Palisade Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Palisade Bio, Inc. includes Dr. Kenneth Carter as Executive Chairman and Principal Executive Officer, with board members Dr. Mary Gray, Dr. David Mazzo, Dr. Cristina Csimma, Mr. Scott Ogilvie, and Mr. Sandford Smith, the latter three serving as independent directors.

View full answer

Is Palisade Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Palisade Bio, Inc. is in a bearish trend with weak strength, indicated by daily moving averages and bearish signals, despite a mildly bullish weekly MACD, and has underperformed the S&P 500 with a year-to-date return of -63.76%.

View full answer

Compare Palisade Bio, Inc. with Similar Stocks

Sonoma Pharmaceuticals, Inc.Synaptogenix, Inc.Tempest Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 214 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.56

Return on Equity

-364.57%

Price to Book

66.67

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

79.99%

6 Months

4.17%

1 Year

-67.46%

2 Years

-93.75%

3 Years

-99.63%

4 Years

-99.95%

5 Years

-99.96%

Palisade Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-0.20%

EBIT Growth (5y)

-12.30%

EBIT to Interest (avg)

-12.12

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.35

Sales to Capital Employed (avg)

0.02

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.32%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.63

EV to EBIT

0.28

EV to EBITDA

0.28

EV to Capital Employed

2.08

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

733.08%

ROE (Latest)

-246.48%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (0.02%)

Foreign Institutions

Held by 3 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -3.57% vs -27.27% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.90",
          "val2": "-2.80",
          "chgp": "-3.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.90",
          "val2": "-2.80",
          "chgp": "-3.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -17.07% vs 15.17% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.90",
          "val2": "-12.80",
          "chgp": "-16.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.40",
          "val2": "-12.30",
          "chgp": "-17.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-51,380.00%",
          "chgp": "5,138.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.90

-2.80

-3.57%

Interest

0.00

Exceptional Items

0.30

-0.00

Consolidate Net Profit

-2.90

-2.80

-3.57%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is -3.57% vs -27.27% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

0.30

-100.00%

Operating Profit (PBDIT) excl Other Income

-14.90

-12.80

-16.41%

Interest

0.00

Exceptional Items

0.00

-0.20

100.00%

Consolidate Net Profit

-14.40

-12.30

-17.07%

Operating Profit Margin (Excl OI)

0.00%

-51,380.00%

5,138.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -17.07% vs 15.17% in Dec 2023

All Annual Results

Company CV

About Palisade Bio, Inc.

Palisade Bio, Inc.

Pharmaceuticals & Biotechnology

Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.

Company Coordinates

Company Details

20271 Goldenrod Ln Ste 2024 , GERMANTOWN MD : 20876

Tel: 1 301 3664841

https://senecabio.com/

Registrar Details

Palisade Bio, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Palisade Bio, Inc.?

Watch in Real-Time

What does Palisade Bio, Inc. do?

Who are in the management team of Palisade Bio, Inc.?

Is Palisade Bio, Inc. technically bullish or bearish?

Compare Palisade Bio, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Palisade Bio, Inc.

Company Coordinates